The goal of the Pediatric Malignancies Program is to improve, through basic and clinical translational research, the outcome for children with cancer. Pediatric cancers are unique in their morphology, tissues of origin and behavior. They provide an opportunity to understand the link between normal development and the aberrations of malignancy, the interactions of genetics and environment, and the late effects of treatment.
The aims of the program are the following: (1) to elucidate the molecular pathogenesis of childhood cancer by identifying important genes, proteins and pathways;(2) to translate this information into improved diagnosis, classification, prediction of outcome, and treatment selection and epidemiological studies;(3) to develop and conduct clinical Phase I, II and III trials to improve survival;(4) to study the late effects of therapy and improve the quality of life for survivors;and (5) to train fellows, residents and students in pediatric malignancies and mentor junior faculty with basic and clinical research training awards. The Pediatric Malignancies Program has 25 members from 10 different departments. The main research interests of the Pediatric Malignancies Program are molecular and genomic studies of pediatric malignancies (particularly neuroblastoma, CMS tumors, leukemias and retinoblastoma), developmental therapeutics in neuroblastoma, brain tumors, and leukemia, and late effects and epidemiology of childhood cancer. The goals of the Program are enhanced by close synergy with Cancer Center Programs such as Hematopoietic Malignancies, Neurologic Oncology, and Tobacco Control, as well as many interactions with scientists in other, basic science Programs, such as Cancer and Immunity, Cell Cycling and Signaling, and Cancer Genetics, and with the Cores. The Program has $4,444,595 Total peer reviewed support for the last budget year. The Program has 17% intra-programmatic and 40% inter-programmatic publications. PERFORMANCE SITE(S) (organization, city, state) UCSF Comprehensive Cancer Center San Francisco, California PHS 398/2590 (Rev. 09/04) Page Pediatric Malignancies Program

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA082103-13
Application #
8292265
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2011-06-01
Budget End
2012-05-31
Support Year
13
Fiscal Year
2011
Total Cost
$68,776
Indirect Cost
Name
University of California San Francisco
Department
Type
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Dvorak, Christopher C; Satwani, Prakash; Stieglitz, Elliot et al. (2018) Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group study. Pediatr Blood Cancer 65:e27034
Fan, Qi Wen; Nicolaides, Theodore P; Weiss, William A (2018) Inhibiting 4EBP1 in Glioblastoma. Clin Cancer Res 24:14-21
Sannino, Sara; Guerriero, Christopher J; Sabnis, Amit J et al. (2018) Compensatory increases of select proteostasis networks after Hsp70 inhibition in cancer cells. J Cell Sci 131:
Lam, Christine; Ferguson, Ian D; Mariano, Margarette C et al. (2018) Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment. Haematologica 103:1218-1228
Truillet, Charles; Parker, Matthew F L; Huynh, Loc T et al. (2018) Measuring glucocorticoid receptor expression in vivo with PET. Oncotarget 9:20399-20408
Phillips, Kathryn A; Trosman, Julia R; Deverka, Patricia A et al. (2018) Insurance coverage for genomic tests. Science 360:278-279
Phillips, Kathryn A (2018) Evolving Payer Coverage Policies on Genomic Sequencing Tests: Beginning of the End or End of the Beginning? JAMA 319:2379-2380
Puri, Sapna; Roy, Nilotpal; Russ, Holger A et al. (2018) Replication confers ? cell immaturity. Nat Commun 9:485
An, Zhenyi; Aksoy, Ozlem; Zheng, Tina et al. (2018) Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies. Oncogene 37:1561-1575
Behr, Spencer C; Villanueva-Meyer, Javier E; Li, Yan et al. (2018) Targeting iron metabolism in high-grade glioma with 68Ga-citrate PET/MR. JCI Insight 3:

Showing the most recent 10 out of 192 publications